)
Visual
earnings real time
VYNE Therapeutics (VYNE) investor relations material
VYNE Therapeutics M&A Announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.M&A Announcement summary17 Dec, 2025
Merger overview and strategic rationale
VYNE and Yarrow Bioscience will merge in an all-stock transaction, with Yarrow's CEO Rebecca Frey, Pharm.D., leading the combined company as CEO and Lori Payton, Ph.D., as Chief Development Officer.
The merger follows a comprehensive strategic review aimed at maximizing stockholder value, including a cash dividend for VYNE stockholders and continued ownership in the new entity.
Pre-merger VYNE stockholders will receive a cash dividend of $14.5–$16.5 million and own about 3% of the combined company; Yarrow stockholders will own about 97%.
The combined company will be named Yarrow Bioscience Incorporated and trade on Nasdaq under the ticker YARW, with the merger expected to close in Q2 next year, pending shareholder and regulatory approvals.
The board of both companies unanimously approved the transaction, subject to customary closing conditions including SEC registration and shareholder approval.
Financial position and investor support
The combined company is expected to have a cash runway into 2028, supported by $200 million in pre-closing private placements.
Leading healthcare investors, including RTW Investments, OrbiMed Advisors, Janus Henderson Investors, and others, participated in the financing.
Gibson, Dunn & Crutcher LLP and Cooley LLP are providing legal counsel, with Wedbush Securities and LifeSci Capital as financial advisors.
Yarrow's pipeline and clinical strategy
Yarrow focuses on developing YB-101, a first-in-class humanized monoclonal TSHR antibody for Graves' disease and Thyroid Eye Disease (TED).
YB-101 was in-licensed from GenSci, with Yarrow holding global ex-China rights; GenSci is running a phase I trial in China, with Phase 1 data in TED expected from China.
Yarrow plans to start a phase 1b/2b trial for Graves' disease in the US and other territories in the first half of 2026.
How does YB-101 differentiate from IGF-1R therapies?
Update on YB-101's China TED trial progress.
Why is VYNE's post-merger ownership only 3%?
YB-101 US trial start vs China data readout
YB-101 vs teprotumumab differentiation
Investor syndicate's strategic value beyond capital
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next VYNE Therapeutics earnings date
Q4 20255 Mar, 2026
Next VYNE Therapeutics earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing proprietary therapeutics for the treatment of immuno-inflammatory conditions. The company's product pipeline includes VYN201, a locally administered pan-BET inhibitor designed to address diseases involving multiple inflammatory cell signaling pathways with minimal systemic exposure. Additionally, VYNE is working on VYN202, a BD2-selective oral small molecule, and FMX114, a combination gel in clinical trials for atopic dermatitis. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage